-
[show abstract]
[hide abstract]
ABSTRACT: A series of (4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepine-5-ylidene)acetamide derivatives were optimized to achieve potent agonistic activity, both in vitro and in vivo, for the arginine vasopressin V(2) receptor, resulting in the eventual discovery of compound 1g. Molecular modeling of compound 1g with V(2) receptor was also examined to evaluate the binding mode of this series of compounds.
Bioorganic & medicinal chemistry 10/2009; 17(24):8161-7. · 2.82 Impact Factor
-
Issei Tsukamoto,
Hiroyuki Koshio,
Takahiro Kuramochi,
Chikashi Saitoh,
Hiroko Yanai-Inamura,
Chika Kitada-Nozawa,
Eisaku Yamamoto,
Takeyuki Yatsu,
Yoshiaki Shimada,
Shuichi Sakamoto,
Shin-ichi Tsukamoto
[show abstract]
[hide abstract]
ABSTRACT: A series of (4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene)acetamide derivatives was synthesized, and their structure-activity relationships were examined in order to identify potent and selective arginine vasopressin V(2) receptor agonists. Attempts to substitute other chemical groups in place of the 2-pyridilmethyl moiety of 1a led to the discovery that potent V(2) binding affinity could be obtained with a wide range of functional groups. This structural tolerance allowed for the manipulation of other attributes, such as selectivity against V(1a) receptor affinity or avoidance of the undesirable inhibition of cytochrome P450 (CYP), without losing potent affinity for the V(2) receptor. Some representative compounds obtained in this study were also found to decrease urine volume in awake rats.
Bioorganic & medicinal chemistry 04/2009; 17(8):3130-41. · 2.82 Impact Factor
-
Issei Tsukamoto,
Hiroyuki Koshio,
Seijiro Akamatsu,
Takahiro Kuramochi,
Chikashi Saitoh,
Takeyuki Yatsu,
Hiroko Yanai-Inamura,
Chika Kitada,
Eisaku Yamamoto,
Shuichi Sakamoto,
Shin-Ichi Tsukamoto
[show abstract]
[hide abstract]
ABSTRACT: The present work describes the discovery of novel series of (4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepine-5-ylidene)acetamide derivatives as arginine vasopressin (AVP) V(2) receptor agonists. By replacing the amide juncture in YM-35278 with a direct ring connection gave compound 10a, which acts as a V(2) receptor agonist. These studies provided the potent, orally active non-peptidic V(2) receptor agonists 10a and 10j.
Bioorganic & medicinal chemistry 10/2008; 16(21):9524-35. · 2.82 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Ca(2+) overload in myocardial cells is responsible for arrhythmia. Sodium-calcium exchanger (NCX) inhibitors are more effective than sodium-hydrogen exchanger (NHE) inhibitors with regard to modulation of Ca(2+) overload, because NCX inhibitors can directly inhibit the influx of Ca(2+) into cells. NCX is an attractive target for the treatment of heart failure and ischemia-reperfusion. We have designed and synthesized a series of N-(2-aminopyridin-4-ylmethyl)nicotinamide derivatives, based on compound 5. We have discovered a novel NCX inhibitor (23 h) with an IC(50) value of 0.12 microM against reverse NCX. The inhibitory activities of our NCX inhibitors against cytochrome P450 were also evaluated. The effects on heart failure and the pharmacokinetic profile of compound 23 h are discussed.
Bioorganic & Medicinal Chemistry 07/2005; 13(12):4022-36. · 2.92 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: The sodium-calcium exchanger (NCX) transports Na+ and Ca2+ ions, and controls the Ca2+ concentration in myocytes. Calcium overload is induced via activation of reverse NCX, and is responsible for reperfusion injury in heart failure. Hence, NCX is an attractive target for prevention and treatment of reperfusion arrhythmias, myocardial contracture, and necrosis. We have synthesized a series of 6-{4-[(3-fluorobenzyl)oxy]phenoxy}nicotinamide derivatives, and evaluated their inhibitory activity against the reverse and forward modes of NCX. N-(3-Aminobenzyl)-6-{4-[(3-fluorobenzyl)oxy]phenoxy}nicotinamide (8) was shown to be a potent inhibitor of reverse NCX activity, with an IC50 value of 0.24 microM. A QSAR study showed that inhibition of reverse NCX activity by 6-{4-[(3-fluorobenzyl)oxy]phenoxy}nicotinamide derivatives is multiply dependent on the hydrophobicity (pi) and the shape (B(iv)) of the substituent at the 3-position of the phenyl ring.
Bioorganic & Medicinal Chemistry 03/2005; 13(3):717-24. · 2.92 Impact Factor
